Medtronic appeal draws U.S. Supreme Court interest; U.K. regulators accused of helping firm avoid breast implant reparations;

@FierceMedDev: Edwards' stock starts rebounding after FDA expanded approval for Sapien valve. ICYMI Friday | Follow @FierceMedDev

@MarkHFierce: Atossa is issuing a voluntary recall of its breast cancer test to address FDA regulatory concerns. News | Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceBiotech's new mobile app! Here's some more info | Follow @MichaelGFierce

> Medtronic's ($MDT) appeal of a lawsuit from a man who became a paraplegic after receiving an implant that infuses pain medication into the spine is drawing interest from the U.S. Supreme court. Story

> British regulators are accused of helping a cosmetic surgery outfit avoid paying compensation to victims of the PIP breast implant scandal. Story

> Zilico in the U.K. won a CE mark for its new cervical cancer diagnostics device. Story

> LifeCell is rolling out a new device designed to enable the transfer of fat in aesthetic and reconstructive procedures. Item

> Florida's NovaBone Products, a maker of orthopedic and dental biomaterials, is pursuing a sizeable expansion. Item

> Nucletron in Georgia won 510(k) clearance for a new brachytherapy system to treat patients with skin cancer. Story

Biotech News

@FierceBiotech: Still trending: What happens to the  in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Pharma companies paid $25K to attend academics' summit on FDA trial rules. Pay to play. Report | Follow @JohnCFierce

@DamianFierce: Analyst: Bet on another boom for big CROs. More from FierceCRO | Follow @DamianFierce

@EmilyMFierce: Chemical in red wine kills cancer cells even after it's metabolized. Story from FierceBiotech Research | Follow @EmilyMFierce

> Novo Nordisk betting $3.7B on a blockbuster oral diabetes drug market. Story

> GlaxoSmithKline's Duchenne MD drug mirrors placebo effect in PhIII. More

> GlycoMimetics, Karyopharm ride the wave of new biotech IPOs. Article

Pharma News

@FiercePharma: Sanofi chief's latest growth promise: Q4 will bring it. Story | Follow @FiercePharma

@EricPFierce: FDA approved another new hot flash drug, this one from Pfizer, Ligand. ICYMI last week | Follow @EricPFierce

@CarlyHFierce: ICYMI: Activist investor fumes over Otsuka bid for Astex. More | Follow @CarlyHFierce

> J&J's Doxil shortage to last until at least end of 2014. Article

> Merck, AstraZeneca, Pfizer top list of biggest pharma job-cutters. More

> Forget drug-sales forecasts, study finds: They're mostly wrong. Report

CRO News

> Analyst: Bet on another boom for big CROs. Report

> Covance launches lab management service to cut study costs. Article

> Biocon: Syngene is Asia's fastest-growing CRO. Item

> Boehringer pulls plug on CMO biz, plots 1,100 job cuts. Story

> CRO TranScrip reaches into Hong Kong. News

> AMRI snags drug development deal with U.K. government. More

Biotech IT News

> IBM updates open-source Big Data disease modeling platform. Report

> Low-profile cloud service provider steps into limelight. Item

> Ambitious U.K. genome project looks for industry input. News

> Bioinformatics projects stall as shutdown stops NIH funding. Story

> Bill advances case for nationwide track-and-trace databases. More

> Experts tip bioinformatics collaborations to improve breast cancer care. Article

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.